Long-term debt · 2012–2021
Supernus Pharmaceuticals long-term debt
$379M+1,532.9% · FY2021
Supernus Pharmaceuticals (SUPN) reported $379M in long-term debt for fiscal 2021, +1,532.9% year on year.
Long-term debt — Long-term debt is borrowing due more than a year out. A large figure is normal for capital-intensive businesses and says nothing on its own about financial health.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2012–2021 compound annual growth +36.4%
Long-term debt at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Supernus Pharmaceuticals long-term debt |url=https://companiesranked.com/en/company/supernus-pharmaceuticals/long-term-debt |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Supernus Pharmaceuticals long-term debt. CompaniesRanked. https://companiesranked.com/en/company/supernus-pharmaceuticals/long-term-debtBibTeX
@misc{companiesranked-en-company-supernus-pharmaceuticals-long-term-debt-2026,
author = {{CompaniesRanked}},
title = {{Supernus Pharmaceuticals long-term debt}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/supernus-pharmaceuticals/long-term-debt}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.